Roche NT-proBNP

Elecsys® NT-proBNP
Despite the treatments available, hospitalization and mortality rates remain high.1

Despite the treatments available for heart failure, hospitalization and mortality rates remain high. Optimized heart failure management is the key to improved patient outcomes and quality of life.1,3,4   With over 15 years of clinical evidence, Roche NT-proBNP provides support throughout the continuum of care in heart failure.5-6


Analytical Advantage

NT-proBNP has analytical advantages over BNP

View Full Table

NT-proBNP has analytical advantages over BNP

Characteristics BNP NT-proBNP 7 NT-proBNP Advantages 7 
Age-stratified cutoffs No

Provides more specific representation of disease status, especially in elderly patients 
Half-life 20 minutes


60-120 minutes


Less prone to intra-day variability and contributes to greater detection of heart failure in earlier stages8
Stability Varies 4-24 hours at room temperature


Up to 3 days at room temperature


Greater stability enables lab flexibility for outreach and add-on testing
BNP assays are not standardized across manufacturers

NT-proBNP assays, unlike BNP,  are standardized across manufacturers. In the Emergency Department and inpatient and outpatient settings, consistent results allow for more certainty and confidence in heart failure management.

Clinical Excellence

NT-proBNP delivers confidence when managing patients across the heart failure spectrum.

NT-proBNP detects more cases of early stage heart failure than BNP8

View Full Table

NT-proBNP detects more cases of early stage heart failure than BNP8

AHA/ACC Heart Failure Classification
  Stage A Stage B Stage C Stage D
BNP  (100ng/L) 0% <10% 50% 90%
NT Pro BNP (125ng/L) <10% 25% 90% 100% 
Do you have any questions?
Contact us


1. World Heart Failure Alliance. White Paper: Heart failure, preventing disease and death worldwide. Web:

2. Piotr Ponikowski-Heart Failure- Preventing Disease and Deth Worldwide\
World Heart Failure Alliance.

3. Cowie, M.R. et al. (2013) Improving care for patients are acute heart failure. Retrieved from:

4. Krumholz HM, et al. (2009). Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes.;2(5):407-413

5. Francis et al. (2016). J Am Coll CArdil. 67(3), 330 – 337

6. PubMed Central®: search results for “Roche NT-proBNP heart failure”. Accessed on January 2018, 23rd

7. Reference: Elecsys NT-proBNP Package Insert

8. Emdin M. Clin Chem. 2007;53:71289-71297.